B cell maturation antigen binding proteins
AssigneeHarpoon Therapeutics, Inc.
InventorsHolger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
Life of this patent
Estimating the term…
Abstract
Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.
Claims20
A method for the treatment or amelioration of a B cell lineage cancer in a subject in need thereof, comprising administering to the subject a single domain B cell maturation agent (BCMA) binding protein comprising complementarity determining regions CDR1, CDR2, and CDR3,
- wherein the CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 5, 15, 18, 19, 22, 29, 34, 35, 43, 46, 76, and 95, the CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 118, 121, 122, 125, 126, 129, 133, 137, 147, 156, 164, 173, 174, 190, and 203, and the CDR3 comprises an amino acid sequence set forth as SEQ ID NO:
- 304, and
- wherein the BCMA binding protein is from 80% to 99% identical to the sequence set forth as SEQ ID NO:
- 472.
A method for the treatment or amelioration of a B cell lineage cancer in a subject in need thereof, comprising administering to the subject a single domain BCMA binding protein comprising complementarity determining regions CDR1, CDR2, and CDR3, wherein the CDR1 comprises the amino acid sequence of SEQ ID NO:
- 76, the CDR2 comprises the amino acid sequence of SEQ ID NO:
- 190, and the CDR3 comprises the amino acid sequence of SEQ ID NO:
- 304, and wherein the BCMA binding protein is from 80% to 99% identical to the amino acid sequence set forth as SEQ ID NO:
- 472.
A method for the treatment or amelioration of a B cell lineage cancer in a subject in need thereof, comprising administering to the subject a single domain BCMA binding protein comprising
- (i) a CDR1 comprising the sequence of SEQ ID NO:
- 76, a CDR2 comprising the sequence of SEQ ID NO:
- 190, and a CDR3 comprising the sequence of SEQ ID NO:
- 304;
- (ii) a CDR1 comprising the sequence of SEQ ID NO:
- 114, a CDR2 comprising the sequence of SEQ ID NO:
- 163, and a CDR3 comprising the sequence of SEQ ID NO:
- 304;
- (iii) a CDR1 comprising the sequence of SEQ ID NO:
- 115, a CDR2 comprising the sequence of SEQ ID NO:
- 163, and a CDR3 comprising the sequence of SEQ ID NO:
- 304;
- (iv) a CDR1 comprising the sequence of SEQ ID NO:
- 116, a CDR2 comprising the sequence of SEQ ID NO:
- 174, and a CDR3 comprising the sequence of SEQ ID NO:
- 304;
- or
- (v) a CDR1 comprising the sequence of SEQ ID NO:
- 117, a CDR2 comprising the sequence of SEQ ID NO:
- 174, and a CDR3 comprising the sequence of SEQ ID NO:
- 304.
Dependencies are inferred from the claim text.